Prognostic factors in gliomas: A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic, and molecular markers

V. Ganju, Robert Brian Jenkins, J. R. O'Fallon, B. W. Scheithauer, D. T. Ransom, J. A. Katzmann, D. W. Kimmel

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Background. The ability to divide subsets of patients with glial neoplasms into prognostic groups currently is limited because only a few clinical and pathologic variables are available. The goal of this investigation was to identify biologic factors of potential prognostic value in patients with cerebral gliomas. Methods. This prospective investigation used clinical, pathologic, flow cytometric, cytogenetic, and molecular genetic variables as potential prognostic factors in 207 patients with newly diagnosed gliomas (153 astrocytic tumors of the fibrillary type, 31 oligodendrogliomas, and 23 pilocytic astrocytomas). Classification and regression tree (CART) analysis was performed as part of the multivariate statistical analysis. Results. The age of the patient and the grade of the tumor were confirmed as strong prognostic factors. Cytogenetic or molecular genetic abnormalities of chromosomes 7 and 10 were associated with poor survival in univariate analysis (P < 0.0001). CART multivariate analysis identified several subsets of patients with different prognoses. In the subset of patients younger than 66.5 years with Grade 4 tumors, the survival time was longer for those with aneuploid tumors than for those with nonaneuploid tumors. In the subset of patients with Grades 1-3 tumors, the survival time was longer for those whose tumors had a %G2M of less than 6.9 than for those whose tumors had a %G2M of 6.9 or greater. Conclusion. This investigation provides further evidence that flow cytometry, cytogenetic, and molecular genetic factors that may have prognostic value in patients with gliomas can be identified.

Original languageEnglish (US)
Pages (from-to)920-927
Number of pages8
JournalCancer
Volume74
Issue number3 SUPPL.
DOIs
StatePublished - 1994

Fingerprint

Glioma
Cytogenetics
Multivariate Analysis
Neoplasms
Molecular Biology
Astrocytoma
Survival
Oligodendroglioma
Chromosomes, Human, Pair 10
Chromosomes, Human, Pair 7
Biological Factors
Aneuploidy
Neuroglia
Flow Cytometry
Regression Analysis

Keywords

  • astrocytoma
  • cytogenetics
  • flow cytometry
  • glioma
  • molecular genetics
  • prognosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prognostic factors in gliomas : A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic, and molecular markers. / Ganju, V.; Jenkins, Robert Brian; O'Fallon, J. R.; Scheithauer, B. W.; Ransom, D. T.; Katzmann, J. A.; Kimmel, D. W.

In: Cancer, Vol. 74, No. 3 SUPPL., 1994, p. 920-927.

Research output: Contribution to journalArticle

Ganju, V. ; Jenkins, Robert Brian ; O'Fallon, J. R. ; Scheithauer, B. W. ; Ransom, D. T. ; Katzmann, J. A. ; Kimmel, D. W. / Prognostic factors in gliomas : A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic, and molecular markers. In: Cancer. 1994 ; Vol. 74, No. 3 SUPPL. pp. 920-927.
@article{eb08745a8c64479bbf527e4d049e15ec,
title = "Prognostic factors in gliomas: A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic, and molecular markers",
abstract = "Background. The ability to divide subsets of patients with glial neoplasms into prognostic groups currently is limited because only a few clinical and pathologic variables are available. The goal of this investigation was to identify biologic factors of potential prognostic value in patients with cerebral gliomas. Methods. This prospective investigation used clinical, pathologic, flow cytometric, cytogenetic, and molecular genetic variables as potential prognostic factors in 207 patients with newly diagnosed gliomas (153 astrocytic tumors of the fibrillary type, 31 oligodendrogliomas, and 23 pilocytic astrocytomas). Classification and regression tree (CART) analysis was performed as part of the multivariate statistical analysis. Results. The age of the patient and the grade of the tumor were confirmed as strong prognostic factors. Cytogenetic or molecular genetic abnormalities of chromosomes 7 and 10 were associated with poor survival in univariate analysis (P < 0.0001). CART multivariate analysis identified several subsets of patients with different prognoses. In the subset of patients younger than 66.5 years with Grade 4 tumors, the survival time was longer for those with aneuploid tumors than for those with nonaneuploid tumors. In the subset of patients with Grades 1-3 tumors, the survival time was longer for those whose tumors had a {\%}G2M of less than 6.9 than for those whose tumors had a {\%}G2M of 6.9 or greater. Conclusion. This investigation provides further evidence that flow cytometry, cytogenetic, and molecular genetic factors that may have prognostic value in patients with gliomas can be identified.",
keywords = "astrocytoma, cytogenetics, flow cytometry, glioma, molecular genetics, prognosis",
author = "V. Ganju and Jenkins, {Robert Brian} and O'Fallon, {J. R.} and Scheithauer, {B. W.} and Ransom, {D. T.} and Katzmann, {J. A.} and Kimmel, {D. W.}",
year = "1994",
doi = "10.1002/1097-0142(19940801)74:3<920::AID-CNCR2820740320>3.0.CO;2-4",
language = "English (US)",
volume = "74",
pages = "920--927",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3 SUPPL.",

}

TY - JOUR

T1 - Prognostic factors in gliomas

T2 - A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic, and molecular markers

AU - Ganju, V.

AU - Jenkins, Robert Brian

AU - O'Fallon, J. R.

AU - Scheithauer, B. W.

AU - Ransom, D. T.

AU - Katzmann, J. A.

AU - Kimmel, D. W.

PY - 1994

Y1 - 1994

N2 - Background. The ability to divide subsets of patients with glial neoplasms into prognostic groups currently is limited because only a few clinical and pathologic variables are available. The goal of this investigation was to identify biologic factors of potential prognostic value in patients with cerebral gliomas. Methods. This prospective investigation used clinical, pathologic, flow cytometric, cytogenetic, and molecular genetic variables as potential prognostic factors in 207 patients with newly diagnosed gliomas (153 astrocytic tumors of the fibrillary type, 31 oligodendrogliomas, and 23 pilocytic astrocytomas). Classification and regression tree (CART) analysis was performed as part of the multivariate statistical analysis. Results. The age of the patient and the grade of the tumor were confirmed as strong prognostic factors. Cytogenetic or molecular genetic abnormalities of chromosomes 7 and 10 were associated with poor survival in univariate analysis (P < 0.0001). CART multivariate analysis identified several subsets of patients with different prognoses. In the subset of patients younger than 66.5 years with Grade 4 tumors, the survival time was longer for those with aneuploid tumors than for those with nonaneuploid tumors. In the subset of patients with Grades 1-3 tumors, the survival time was longer for those whose tumors had a %G2M of less than 6.9 than for those whose tumors had a %G2M of 6.9 or greater. Conclusion. This investigation provides further evidence that flow cytometry, cytogenetic, and molecular genetic factors that may have prognostic value in patients with gliomas can be identified.

AB - Background. The ability to divide subsets of patients with glial neoplasms into prognostic groups currently is limited because only a few clinical and pathologic variables are available. The goal of this investigation was to identify biologic factors of potential prognostic value in patients with cerebral gliomas. Methods. This prospective investigation used clinical, pathologic, flow cytometric, cytogenetic, and molecular genetic variables as potential prognostic factors in 207 patients with newly diagnosed gliomas (153 astrocytic tumors of the fibrillary type, 31 oligodendrogliomas, and 23 pilocytic astrocytomas). Classification and regression tree (CART) analysis was performed as part of the multivariate statistical analysis. Results. The age of the patient and the grade of the tumor were confirmed as strong prognostic factors. Cytogenetic or molecular genetic abnormalities of chromosomes 7 and 10 were associated with poor survival in univariate analysis (P < 0.0001). CART multivariate analysis identified several subsets of patients with different prognoses. In the subset of patients younger than 66.5 years with Grade 4 tumors, the survival time was longer for those with aneuploid tumors than for those with nonaneuploid tumors. In the subset of patients with Grades 1-3 tumors, the survival time was longer for those whose tumors had a %G2M of less than 6.9 than for those whose tumors had a %G2M of 6.9 or greater. Conclusion. This investigation provides further evidence that flow cytometry, cytogenetic, and molecular genetic factors that may have prognostic value in patients with gliomas can be identified.

KW - astrocytoma

KW - cytogenetics

KW - flow cytometry

KW - glioma

KW - molecular genetics

KW - prognosis

UR - http://www.scopus.com/inward/record.url?scp=0028095051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028095051&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19940801)74:3<920::AID-CNCR2820740320>3.0.CO;2-4

DO - 10.1002/1097-0142(19940801)74:3<920::AID-CNCR2820740320>3.0.CO;2-4

M3 - Article

C2 - 8039120

AN - SCOPUS:0028095051

VL - 74

SP - 920

EP - 927

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3 SUPPL.

ER -